Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements Recruiting Phase 2 Trials for Zanubrutinib (DB15035)

Also known as: Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements

IndicationStatusPhase
DBCOND0131475 (Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements)Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT05202782Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell LymphomaTreatment